| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_050fc7b82c5d17d9aeb63a7cdcc546b3 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-76
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2818
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61N2005-1098
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2300-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-395 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2818
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-52
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-45
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-3015
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K41-0038
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61N5-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K41-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61N5-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-45 |
| filingDate |
2019-12-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2020-12-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8af2b91f60721d6ffa28407e0d67b8dd
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1fb34677afa2b7bdf89518feec15cc30
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_fd76a905d2d46f3a1dd50224a8b41077
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9be287bd1ca2cdc728c8230617f4f8db
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_41d21e2b0231ff294cbd55ee6afa3c3e |
| publicationDate |
2020-12-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
KR-102195221-B1 |
| titleOfInvention |
Pharmaceutical composition for combination of radiotherapy for treating triple negative breast cancer comprising phosphatidylinositol 3-kinase inhibitor and programmed cell death protein 1 inhibitor |
| abstract |
The present invention provides a pharmaceutical composition for use in combination with radiation therapy for the treatment of triple negative breast cancer. More specifically, the pharmaceutical composition comprises a PD-1 inhibitor and a PI3Kγδ inhibitor, and by using the PD-1 inhibitor and a PI3Kγδ inhibitor in combination with radiation therapy, it has superior tumor suppression and immunity enhancing effects compared to the monotherapy of each therapeutic agent. . |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2022171121-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2023014206-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2023080337-A1 |
| priorityDate |
2019-12-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |